S&P 500   3,384.29 (+1.46%)
DOW   27,971.35 (+1.89%)
QQQ   279.21 (+1.18%)
AAPL   116.24 (+1.88%)
MSFT   210.54 (+1.58%)
FB   263.88 (+0.80%)
GOOGL   1,474.63 (+0.59%)
AMZN   3,187.63 (+1.36%)
TSLA   429.14 (+2.40%)
NVDA   541.91 (+2.43%)
BABA   291.84 (+5.38%)
CGC   14.44 (-0.41%)
GE   6.27 (+2.45%)
MU   47.38 (-6.57%)
AMD   81.96 (+0.23%)
T   28.60 (+1.06%)
F   6.71 (+1.67%)
ACB   4.74 (+1.28%)
GILD   62.85 (+1.21%)
NFLX   500.14 (+1.35%)
DIS   124.84 (-0.45%)
BA   169.30 (+3.48%)
BAC   24.30 (+2.23%)
S&P 500   3,384.29 (+1.46%)
DOW   27,971.35 (+1.89%)
QQQ   279.21 (+1.18%)
AAPL   116.24 (+1.88%)
MSFT   210.54 (+1.58%)
FB   263.88 (+0.80%)
GOOGL   1,474.63 (+0.59%)
AMZN   3,187.63 (+1.36%)
TSLA   429.14 (+2.40%)
NVDA   541.91 (+2.43%)
BABA   291.84 (+5.38%)
CGC   14.44 (-0.41%)
GE   6.27 (+2.45%)
MU   47.38 (-6.57%)
AMD   81.96 (+0.23%)
T   28.60 (+1.06%)
F   6.71 (+1.67%)
ACB   4.74 (+1.28%)
GILD   62.85 (+1.21%)
NFLX   500.14 (+1.35%)
DIS   124.84 (-0.45%)
BA   169.30 (+3.48%)
BAC   24.30 (+2.23%)
S&P 500   3,384.29 (+1.46%)
DOW   27,971.35 (+1.89%)
QQQ   279.21 (+1.18%)
AAPL   116.24 (+1.88%)
MSFT   210.54 (+1.58%)
FB   263.88 (+0.80%)
GOOGL   1,474.63 (+0.59%)
AMZN   3,187.63 (+1.36%)
TSLA   429.14 (+2.40%)
NVDA   541.91 (+2.43%)
BABA   291.84 (+5.38%)
CGC   14.44 (-0.41%)
GE   6.27 (+2.45%)
MU   47.38 (-6.57%)
AMD   81.96 (+0.23%)
T   28.60 (+1.06%)
F   6.71 (+1.67%)
ACB   4.74 (+1.28%)
GILD   62.85 (+1.21%)
NFLX   500.14 (+1.35%)
DIS   124.84 (-0.45%)
BA   169.30 (+3.48%)
BAC   24.30 (+2.23%)
S&P 500   3,384.29 (+1.46%)
DOW   27,971.35 (+1.89%)
QQQ   279.21 (+1.18%)
AAPL   116.24 (+1.88%)
MSFT   210.54 (+1.58%)
FB   263.88 (+0.80%)
GOOGL   1,474.63 (+0.59%)
AMZN   3,187.63 (+1.36%)
TSLA   429.14 (+2.40%)
NVDA   541.91 (+2.43%)
BABA   291.84 (+5.38%)
CGC   14.44 (-0.41%)
GE   6.27 (+2.45%)
MU   47.38 (-6.57%)
AMD   81.96 (+0.23%)
T   28.60 (+1.06%)
F   6.71 (+1.67%)
ACB   4.74 (+1.28%)
GILD   62.85 (+1.21%)
NFLX   500.14 (+1.35%)
DIS   124.84 (-0.45%)
BA   169.30 (+3.48%)
BAC   24.30 (+2.23%)
Log in
NASDAQ:CCXI

ChemoCentryx Stock Forecast, Price & News

$55.13
+1.60 (+2.99 %)
(As of 09/30/2020 01:20 PM ET)
Add
Compare
Today's Range
$53.21
Now: $55.13
$55.28
50-Day Range
$46.35
MA: $51.96
$55.72
52-Week Range
$6.44
Now: $55.13
$65.43
Volume7,197 shs
Average Volume663,362 shs
Market Capitalization$3.80 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.74
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Read More
ChemoCentryx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.13 million
Book Value$1.14 per share

Profitability

Net Income$-55,490,000.00

Miscellaneous

Employees82
Market Cap$3.80 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$55.13
+1.60 (+2.99 %)
(As of 09/30/2020 01:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

How has ChemoCentryx's stock price been impacted by Coronavirus?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has increased by 32.5% and is now trading at $55.06.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ChemoCentryx?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ChemoCentryx
.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for ChemoCentryx
.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) announced its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.63. The biopharmaceutical company earned $49.44 million during the quarter, compared to the consensus estimate of $8.31 million. ChemoCentryx had a negative net margin of 39.19% and a negative return on equity of 19.57%.
View ChemoCentryx's earnings history
.

What price target have analysts set for CCXI?

9 brokers have issued 12-month price objectives for ChemoCentryx's stock. Their forecasts range from $54.00 to $100.00. On average, they expect ChemoCentryx's stock price to reach $72.44 in the next year. This suggests a possible upside of 31.6% from the stock's current price.
View analysts' price targets for ChemoCentryx
.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 61, Pay $968.76k)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 57, Pay $696.65k)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 59, Pay $563.8k)
  • Ms. Kari E. Leetch, Sr. VP of HR
  • Dr. Catherine Lee Kelleher, Sr. VP of Clinical Devel.

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $55.06.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $3.79 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.